Monoclonal antibody could be potential acute respiratory distress syndrome treatment

Patients with moderate to severe acute respiratory distress syndrome receiving a monoclonal antibody treatment vs. placebo had similar safety profiles and more ventilator-free days, according to phase 2a trial results.These findings on ALT-100, an extracellular nicotinamide phosphoribosyltransferase (eNAMPT)-neutralizing monoclonal antibody (mAb), were published in American Journal of Respiratory